Advice

following an abbreviated submission:

midodrine hydrochloride (Bramox®) is accepted for use within NHS Scotland.

Indication under review: in adults for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.

Midodrine hydrochloride (Bramox®) 5mg tablets have been shown to be bioequivalent to the unlicensed midodrine 5mg product currently in use in NHS Scotland. The availability of midodrine hydrochloride (Bramox®) will allow the prescribing of a licensed medicinal product, with a resultant small net budget impact, based on estimates from primary and secondary prescribing and expenditure data from 2013/14.

Download detailed advice110KB (PDF)

Download

Medicine details

Medicine name:
midodrine hydrochloride (Bramox)
SMC ID:
1094/15
Indication:
in adults for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.
Pharmaceutical company
Brancaster Pharma Limited
BNF chapter
Endocrine system
Submission type
Abbreviated
Status
Accepted
Date advice published
12 October 2015